Point of care molecular diagnostic: a rapidly growing trend in clinical laboratories
The global point of care molecular diagnostic market is expected to grow at a CAGR of 6.4% during the forecast period 2019-2026.
Point of care molecular diagnosticmarket is expecting a healthy growth during the coming future. During last few years there is a significant increase in the prevalence of infectious diseases, and other chronic diseases. Increasing prevalence of tuberculosis, hepatitis and cancer has increase the demand for the point of care molecular diagnostic test. According to the research conducted by the Johns Hopkins University, in 2012, 1.4 million people were suffering from chronic hepatitis B.Additionally, according to the World Health Organization, in 2012, 14.1 million people were suffering from cancer. Increasing prevalence of cancer and infectious diseases has driven the growth of the market. Moreover, increasing healthcare spending and government support have fuelled the growth of the market.
Segmental Analysis
The global point of care molecular diagnostic market is segmented on the basis of techniques, applications and end users. On the basis of techniques, the point of care testing molecular diagnostic market is segmented into polymerase chain reaction (PCR), hybridization, DNA diagnostics, microarrays, and others. On the basis of application, the point of care testing molecular diagnostic market is segmented into infectious diseases, hematology, endocrinology, oncology, and other. Infectious diseases are further segmented into hepatitis B, hepatitis C, HIV, TB, MRSA, and others. On the basis of end users, the point of care testing molecular diagnostic market is segmented into professional diagnostics laboratories, molecular diagnostics laboratories, and others.
Geographically, the major share of the market is hold by developed regions.America commands the largest share in the global point of care molecular diagnostic market owing to increasing prevalence of the infectious diseases, high healthcare spending and presence of a number of leading players in this region. Europe accountsfor the second leading position due to availability of funds for research and strong government support. Asia Pacific region shows the fastest growth for the market led by Japan. The Middle East & Africa region is still developing in terms of technology and thus holds the least share in the global market.
The key players in the market are: F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (U.S.), Siemens Healthcare GmbH (Germany), Danaher (U.S.), QIAGEN (Germany), Johnson & Johnson Services, Inc. (U.S.), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Alere (U.S.), and Ortho Clinical Diagnostics (U.S.)
Segmentation Covered
By Techniques
Polymerase Chain Reaction (PCR)
Hybridization
DNA Diagnostics
Microarrays
Others
By Application
Infectious Diseases
Hepatitis B
Hepatitis C
HIV
TB
MRSA
Others
Hematology
Endocrinology
Oncology
Other
By End Users
Professional Diagnostics Laboratories
Molecular Diagnostics Laboratories
Others
By Region
America
North America
U.S.
Canada
South America
Europe
Western Europe
Germany
France
U.K.
Italy
Spain
Rest of Western Europe
Eastern Europe
Asia Pacific
Japan
China
India
Australia
Rest of Asia Pacific
The Middle East & Africa
The Middle East
UAE
Saudi Arabia
Qatar
Rest of the Middle East
Africa
© 2019 Data N Analysis. All Rights Reserved | Design by Data N Analysis